139 related articles for article (PubMed ID: 1916007)
1. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia.
Di Perri R; Coppola G; Ambrosio LA; Grasso A; Puca FM; Rizzo M
J Int Med Res; 1991; 19(4):330-41. PubMed ID: 1916007
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
[TBL] [Abstract][Full Text] [Related]
3. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial.
Barbagallo Sangiorgi G; Barbagallo M; Giordano M; Meli M; Panzarasa R
Ann N Y Acad Sci; 1994 Jun; 717():253-69. PubMed ID: 8030842
[TBL] [Abstract][Full Text] [Related]
4. [Pathological aging of the brain. Personal observations on the use of citicoline].
Palleschi M; Capobianco G
Clin Ter; 1988 Apr; 125(2):121-8. PubMed ID: 2973933
[No Abstract] [Full Text] [Related]
5. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain.
Tayebati SK; Tomassoni D; Nwankwo IE; Di Stefano A; Sozio P; Cerasa LS; Amenta F
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):94-103. PubMed ID: 23244432
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.
Ditzler K
Arzneimittelforschung; 1991 Aug; 41(8):773-80. PubMed ID: 1781796
[TBL] [Abstract][Full Text] [Related]
7. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.
Parnetti L; Amenta F; Gallai V
Mech Ageing Dev; 2001 Nov; 122(16):2041-55. PubMed ID: 11589921
[TBL] [Abstract][Full Text] [Related]
8. Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death.
Lee M; Choi BY; Suh SW
Curr Neuropharmacol; 2018; 16(1):51-58. PubMed ID: 28521701
[TBL] [Abstract][Full Text] [Related]
9. CDP-choline: pharmacological and clinical review.
Secades JJ; Frontera G
Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
[TBL] [Abstract][Full Text] [Related]
10. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type.
Parnetti L; Abate G; Bartorelli L; Cucinotta D; Cuzzupoli M; Maggioni M; Villardita C; Senin U
Drugs Aging; 1993; 3(2):159-64. PubMed ID: 8477148
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of CDP-choline (Nicholin): efficacy As antidepressant treatment.
Salvadorini F; Galeone F; Nicotera M; Ombrato M; Saba P
Curr Ther Res Clin Exp; 1975 Sep; 18(3):513-20. PubMed ID: 810312
[No Abstract] [Full Text] [Related]
12. [Influence of neuroprotectors with choline-positive action on the level of brain-injury markers during acute ischemic stroke].
Vaizova OE; Zautner NA; Alifirova VM; Vengerovskiĭ AI
Eksp Klin Farmakol; 2012; 75(3):7-9. PubMed ID: 22679745
[TBL] [Abstract][Full Text] [Related]
13. [Effect of CDP-choline on senile mental deterioration. Multicenter experience on 237 cases].
Serra F; Diaspri GP; Gasbarrini A; Giancane S; Rimondi A; Tamè MR; Sakellaridis E; Bernardi M; Gasbarrini G
Minerva Med; 1990 Jun; 81(6):465-70. PubMed ID: 2193245
[TBL] [Abstract][Full Text] [Related]
14. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
15. Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo.
Parnetti L; Ambrosoli L; Agliati G; Caratozzolo P; Fossati L; Frattola L; Martucci N; Murri L; Nappi G; Puca FM; Poli A; Girardello R; Senin U
Acta Neurol Scand; 1996 Jun; 93(6):456-63. PubMed ID: 8836309
[TBL] [Abstract][Full Text] [Related]
16. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease.
Franco-Maside A; Caamaño J; Gómez MJ; Cacabelos R
Methods Find Exp Clin Pharmacol; 1994 Oct; 16(8):597-607. PubMed ID: 7760585
[TBL] [Abstract][Full Text] [Related]
17. The serial position effect in mild and moderately severe vascular dementia.
Paul RH; Cohen RA; Moser DJ; Zawacki TM; Gordon N
J Int Neuropsychol Soc; 2002 May; 8(4):584-7. PubMed ID: 12030311
[TBL] [Abstract][Full Text] [Related]
18. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation.
Ambrosio LA; Marchese G; Filippo A; Romano E; Musacchio R
J Int Med Res; 1993; 21(3):138-46. PubMed ID: 8299857
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging correlates of dementia rating scale performance at baseline and 12-month follow-up among patients with vascular dementia.
Sweet LH; Paul RH; Cohen RA; Moser D; Ott BR; Gordon N; Browndyke JN; Shah P; Garrett KD
J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):240-4. PubMed ID: 14653434
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic dyskinesia with CDP-choline.
Arranz J; Ganoza C
Arzneimittelforschung; 1983; 33(7A):1071-3. PubMed ID: 6684469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
